ORIGINAL RESEARCH article

Front. Public Health

Sec. Health Economics

Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1511108

Tight and early HbA1c control of type 2 diabetes mellitus in Spain: quantifying the social value

Provisionally accepted
Paulina  Maravilla-HerreraPaulina Maravilla-Herrera1María  MerinoMaría Merino1*Sara  ArtolaSara Artola2,3Javier  EscaladaJavier Escalada4,5Antonio  Pérez PérezAntonio Pérez Pérez6,7,8Juantxo  RemónJuantxo Remón9Jose Luis  Trillo- MataJose Luis Trillo- Mata10Joan  A Vallès-CallolJoan A Vallès-Callol11Álvaro  Hidalgo-VegaÁlvaro Hidalgo-Vega12,13
  • 1Weber, Madrid, Spain
  • 2José Marvá Health Centre, Madrid, Spain
  • 3Red de Grupos de Estudio en Atención Primaria de Salud (redGDPS) Foundation, Madrid, Spain
  • 4Department of Endocrinology and Nutrition, University Clinic of Navarra, Pamplona, Navarre, Spain
  • 5CIBER Fisiopatología Obesidad y Nutrición (CIBEROBN), Madrid, Madrid, Spain
  • 6Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Balearic Islands, Spain
  • 7Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas – CIBERDEM, Madrid, Spain
  • 8Autonomous University of Barcelona, Barcelona, Catalonia, Spain
  • 9Federación Española de Diabetes, Madrid, Spain
  • 10Pharmacy service of health area Malvarrosa Clinical Department, Conselleria de Sanitat, Valencia, Spain
  • 11Catalan Health Institute (ICS), Barcelona, Catalonia, Spain
  • 12University of Castilla-La Mancha, Department of Economic Analysis and Finances, Toledo, Spain
  • 13Fundación Weber, Madrid, Asturias, Spain

The final, formatted version of the article will be published soon.

Introduction. The aim of this study was to estimate the social value of a tight and early control of patients with type 2 diabetes during the 5 years after diagnosis in Spain, compared to higher hemoglobin A1c (HbA1c) goals. Methods. An economic model based on scientific literature was applied to estimate the 5-year social value of maintaining a tight and early type 2 diabetes control, i.e., HbA1c <6.5%, during the 5 years after diagnosis in Spain, compared with a non-tight control. Areas of analysis included healthcare resource utilization, presence of complications, quality of life, and mortality. Outcomes corresponding to these two types of control (tight vs. non-tight) were multiplied by their unit cost or financial proxy to obtain the economic impact associated to each type of control. Social value was estimated as the reduction of the economic impact of a non-tight control when a tight control is implemented and maintained. Results are expressed in 2021 euros. Results. The economic impact of a tight control during the first 5 years after type 2 diabetes diagnosis was estimated at €1,010 million in Spain (€13,473 per patient), lower than the impact of a non-tight control, which was estimated at €1,127 million (€16,122 per patient) during the same period. Conclusions. Maintaining tight and early control of type 2 diabetes during the first 5 years after diagnosis could generate a positive social value of €2,649 per patient over that period, in terms of better health outcomes, increased quality of life, and decreased premature deaths.

Keywords: socioeconomic impact, type 2 diabetes, glycemic control, Monitoring, complications, Hospitalizations, Quality of Life, Mortality

Received: 14 Oct 2024; Accepted: 31 Mar 2025.

Copyright: © 2025 Maravilla-Herrera, Merino, Artola, Escalada, Pérez Pérez, Remón, Trillo- Mata, Vallès-Callol and Hidalgo-Vega. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: María Merino, Weber, Madrid, Spain

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.